All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Consultant-Needed-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

SK Biopharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

In-Cosmetics Global

Participation Not Confirmed

Update your events

SK Biopharmaceuticals Emerges from Pandemic Delays with Pitch for $822M IPO

Contact the Supplier

Lead Product(s): Cenobamate

Therapeutic Area: Neurology Product Name: Xcopri

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $822.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering June 15, 2020

Details:

Proceeds will be used accelerate further advancement of the Company's pipeline which include, cenobamate, solriamfetol and among others.